UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000040462 |
|---|---|
| Receipt number | R000046184 |
| Scientific Title | A study of biomarker predicting the effort and the adverse event of Nivolumab for unresectable advanced or recurrent esophageal cancer |
| Date of disclosure of the study information | 2020/05/21 |
| Last modified on | 2020/05/20 17:06:28 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A study of biomarker predicting the effort and the adverse event of Nivolumab for unresectable advanced or recurrent esophageal cancer
Acronym
Biomarker research of Nivolumab for esophageal cancer
Scientific Title
A study of biomarker predicting the effort and the adverse event of Nivolumab for unresectable advanced or recurrent esophageal cancer
Scientific Title:Acronym
Biomarker research of Nivolumab for esophageal cancer
Region
| Japan |
Condition
Condition
Unresectable advanced or recurrent esophageal cancer
Classification by specialty
| Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
To search predictive biomarker of Nivolumab treatment for unresectable advanced and recurrent esophageal cancer by immunohistochemical examination and flowcytometry
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Association with effect of treatment and the expression of each factor in the Nivolumab treatment
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)The patients who are Nivolumab single administration plan for unresectable advanced or recurrent esophageal cancer that we aggravated after the cancer chemotherapy.
2)Squamous cell carcinoma is diagnosed by an examination of histopathology.
3)By RECIST(Response Evaluation Criteria in Solid Tumors version 1.1) criteria,
We have at least one measurable lesion or immeasurable lesion.
4)Sex: No object
5)Age (at the agreement acquisition): 20 years or older
6)Performance Status Score (ECOG) is the patient of 0-1
7)The patients whom the radical excision is not indicated for
8)The patients that survival three months or more is anticipated
9)The patients that an agreement is obtained from the person about study entry
Key exclusion criteria
1)The patients whom remarkable malnutrition is found in.The patients receiving a central venous feeding method or the patients needing persistent transfusion by the hospitalization do it with exclusion.
2)The patients whom clear invasion is found in with tumor to the organ (including an aorta and the trachea) near the esophagus lesion. Also, the patients giving a stent therapy in esophagus or the trachea do it with exclusion.
3)We have multiple primary cancer of the activity at the beginning of Nivolumab administration.(Synchronism multiple primary cancer/frequent occurrence cancer and disease-free interval are metachronous multiple primary cancer/frequent occurrence cancers within five years.However, we do not include the lesion of carcinoma in situ and the intramucosal carcinoma equivalency judged to be able to be cured by local treatment in multiple primary cancer/frequent occurrence cancer of the activity.)
4)The patients with a merger of the extensive hypersensitivity reaction for other antibody preparations or the history.
5)The patients who cannot control the pain associated with tumor.
6)The patients who had uncontrollable diabetes.
7)The patients with vascular infection or the history.
8)The patients with the systemic infection to require treatment.
9)It is during the nursing or the patients who may be pregnant during pregnancy.
10)It is the patients with the previous history of treatment with ONO-4538(MDX-1106 or BMS-9365558), antiPD-1/PD-L1/PD-L2/CD137/CTLA-4 antibody or antibody therapy for the purpose other T-cell control or pharmacotherapy in the past.
11)The patients who are judged to be in condition to write ability for agreement by mergers, and the like with dementia.
12)In addition, the patients whom a chief physician, attending staff judged to be inadequate as this study subject
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | Yuichirou |
| Middle name | |
| Last name | Doki |
Organization
Graduated School of Medicine,Osaka University
Division name
Department of Gastroenterological Surgery
Zip code
565-0871
Address
2-2-E2,Yamadaoka,Suita City,Osaka
TEL
06-6879-3251
ydoki@gesurg.med.osaka-u.ac.jp
Public contact
Name of contact person
| 1st name | Tomoki |
| Middle name | |
| Last name | Makino |
Organization
Graduated School of Medicine,Osaka University
Division name
Department of Gastroenterological Surgery
Zip code
565-0871
Address
2-2-E2,Yamadaoka,Suita City,Osaka
TEL
06-6879-3251
Homepage URL
tmakino@gesurg.med.osaka-u.ac.jp
Sponsor or person
Institute
Osaka University
Institute
Department
Personal name
Funding Source
Organization
No
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Osaka Univercity
Address
2-2-E21-25C,Yamadaoka,Suita City,Osaka
Tel
06-6879-3257
mmikamori@gesurg.med.osaka-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 05 | Month | 21 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2020 | Year | 04 | Month | 28 | Day |
Date of IRB
| 2020 | Year | 04 | Month | 28 | Day |
Anticipated trial start date
| 2020 | Year | 04 | Month | 29 | Day |
Last follow-up date
| 2026 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Observation study
Management information
Registered date
| 2020 | Year | 05 | Month | 20 | Day |
Last modified on
| 2020 | Year | 05 | Month | 20 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046184
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
